Innovation at Fujifilm: Human-type collagen protein is produced by introducing genes into yeast cells and cultivating in cell cultures with genetic engineering. Configured in an array design with a high level of cell adhesiveness, the resulting recombinant peptide exhibits high levels of quality, safety, efficacy, and processability, offering great potentials in regenerative medicine and other fields. Recombinant peptides can be shaped into a variety of forms for use as a cellular scaffold in regenerative medicine, a field in which Fujifilm has been strengthening its presence over several years. Recombinant peptide (RCP) is also one of the technology platforms of the Fujifilm Research Laboratories , based in Tilburg, The Netherlands.
Categories: Spotlight - Information about FUJIFILM Europe